Our experts share 30 years of experience, best practices and the latest trends to assist you.
An in‑depth presentation of Miltenyi’s preclinical evaluation of BaEV‑pseudotyped lentiviral vector (BaEV‑LVV) engineered CAR‑NK cells and their translation into a clinical‑grade manufacturing platform for next‑generation cell therapies.
A comprehensive overview of Miltenyi Bioindustry’s end‑to‑end CDMO offerings - from early development through translational process development to GMP‑compliant manufacturing - designed to accelerate cell and gene therapy programs toward clinical and commercial readiness.
Learn how the BaEV (Baboon Envelope) lentiviral vector drives successful CAR-NK production, enabling efficient NK cell engineering and scalable clinical applications in cell and gene therapy.
Join industry leaders from Adaptimmune and Miltenyi Bioindustry as they share insights on the commercialization of lentiviral vectors as a drug substance. This webinar offers valuable lessons for advancing your biopharmaceutical projects.
The significant costs for manufacturing autologous cell therapies continue to create a major barrier to bringing these impactful medicines to more patients. This is primarily due to open process manipulations that require expensive engineering controls and extensive expenses for labor, equipment, materials, cleaning, validation, and a facility footprint. Join industry experts for this timely and important discussion on the use of a fully closed system design that enables commercial scale manufacturing in both centralized and point-of-care settings, and implementation in existing GMP environments.
Developing a cell therapy product is incredibly complex. Speed to clinic and market are imperative to reduce overall costs and maintain competitive market advantages. Leveraging an established lentiviral vector (LVV) process accelerates drug product development. Miltenyi Bioindustry’s LVV platform provides turnkey solutions for cell therapy developers. scalable preclinical batches, validated release assays, a fast-track to GMP manufacturing, and regulatory support.
Given the criticality and often underestimated role of analytics to address clinical and commercial manufacturing requirements, Miltenyi BioIndustry created centers of excellence focusing on analytics that work hand-in hand with process development and technology transfer groups using Miltenyi’s industry-leading cell processing and lentivirus manufacturing platforms.